HOBA
THERAPEUTICS
Developing Restorative Treatments for Pain, Hearing Loss, and Sensory Neuron Disorders
Our Company
Hoba Therapeutic is an early-stage biotech based in Denmark developing innovative treatments for chronic pain disorders and sensorineural hearing loss – indications with a high unmet medical need for safe and efficacious treatments for millions of patients worldwide.
Science
Our science is based on the discovery of a novel family of endogenous human proteins, meteorin and cometin. These are neurotrophic factors involved in the development, growth, survival, and maintenance of nerve cells, supporting glial cells and sensory pathways.
Our focus
Hoba Therapeutics holds the rights to two novel biopharmaceutical drugs
– HB-086 is in late preclinical development for neuropathic pain. The target indications are CIPN and trigeminal neuralgia.
– HB-097 is in preclinical development for sensorineural hearing loss. The target indication is ototoxic hearing loss.
DISCOVER OUR MOVIE
Latest News
Hoba Therapeutics Appoints Jean Combalbert as Chairperson of the Board ofDirectors.
Copenhagen, March 1, 2024
Hoba Therapeutics, a Danish biotech company dedicated to developing novel therapeutic proteins for patients living ...
Hoba Therapeutics raises EUR 23 million in a Series A to advance new drug candidate against chronic neuropathic pain
Copenhagen, December 11, 2023
Hoba Therapeutics, a Novo Holdings founded Danish biotech company dedicated to developing novel therapeutic ...
Eir Ventures invests in Hoba Therapeutics
Copenhagen, July 6, 2022
Hoba Therapeutics, a biotech company developing novel therapeutic proteins for pain, hearing loss, and sensory ...
No results found.